Novartis AG (NVS)

NYSE: NVS · Real-Time Price · USD

113.26

-0.19 (-0.17%)

At close: Apr 30, 2025, 3:59 PM

115.00

1.54%

Pre-market: May 01, 2025, 08:00 AM EDT

-0.17% (1D)

Bid	113.49
Market Cap	226.17B
Revenue (ttm)	51.07B
Net Income (ttm)	11.94B
EPS (ttm)	5.87
PE Ratio (ttm)	19.29
Forward PE	12.64
Analyst	Hold

Ask	119.81
Volume	2,256,635
Avg. Volume (20D)	2,480,700
Open	114.27
Previous Close	113.45
Day's Range	112.81 - 114.51
52-Week Range	96.06 - 120.92
Beta	0.56

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops,...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Nov 7, 1996

Employees 75,883

Stock Exchange NYSE

Ticker Symbol NVS

Website https://www.novartis.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $121, which is an increase of 6.83% from the latest price.

Stock Forecasts

Earnings Surprise

Novartis has released their quartely earnings on Apr 29, 2025:

Revenue of $13.23B exceeds estimates by $243M, with 11.87% YoY growth.

EPS of 2.28 exceeds estimates by 0.20, with 26.67% YoY growth.

Why Price Moved

2 weeks ago

+3.98%

Novartis shares are trading higher after the compa... Unlock content with Pro Subscription

6 months ago

-4.41%

Novartis shares are trading lower. The company reported Q3 financial results

News

1 day ago · benzinga.com

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.

14 hours ago · zacks.com

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

15 hours ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

15 hours ago · seekingalpha.com

Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed

Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US investmen...

17 hours ago · wsj.com

Novartis to Acquire Regulus in $1.7 Billion Deal

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.

17 hours ago · reuters.com

Novartis to buy Regulus Therapeutics for up to $1.7 billion

Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.

1 day ago · youtube.com

We have put ourselves in the right position to manage tariffs: Novartis CEO

Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings.

1 day ago · youtube.com

Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry

Vasant Narasimhan, Novartis CEO, discusses the impact of potential tariffs.

1 day ago · seekingalpha.com

Novartis AG (NVS) Q1 2025 Earnings Call Transcript

Novartis AG (NYSE:NVS ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Ca...

2 days ago · youtube.com

Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well

Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results.

Load More News